Published: 28 June 2021
Author(s): Alessandro Tomelleri, Corrado Campochiaro, Lorenzo Dagna
Issue: July 2021
Section: Editorial

Patients with giant cell arteritis (GCA) represent an extremely fragile population. This frailty arises from the combination of a chronic, highly inflammatory disease affecting patients invariably older than 50 years of age and long-term use of drugs with extensive metabolic side effects such as glucocorticoids [1, 2]. For this reason, management of GCA patients should not only aim at the symptomatic treatment of inflammatory manifestations and the prevention of short and long-term disease-related complications (i.e., sight loss, aortic aneurysms) [3, 4], but should always be weighted in order to minimize the potential treatment-related adverse events.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.